Published in Cancer Weekly, February 7th, 2006
These appointments, along with recent management hires and promotions, are part of a controlled growth strategy to support two drugs in clinical development, advance the company's preclinical pipeline and in-license additional drug candidates.
Herbert J. Conrad became the sixth director on the board of Sapphire Therapeutics in late 2005. He was U.S. president of Roche Pharmaceuticals, a company with which he was affiliated for 33 years in senior...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.